Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Lowered by Wall Street Zen

Posted by Brian Himes on Aug 10th, 2026

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other equities analysts also recently commented on AUPH. Royal Bank Of Canada lifted their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Friday. Weiss Ratings cut shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. Finally, Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $17.67.

View Our Latest Stock Report on AUPH

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $15.85 on Friday. Aurinia Pharmaceuticals has a 52-week low of $10.34 and a 52-week high of $19.25. The stock has a market cap of $2.11 billion, a P/E ratio of 6.92 and a beta of 1.42. The business has a fifty day moving average of $15.95 and a two-hundred day moving average of $15.36. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.24 by $0.04. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.The business had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. On average, research analysts expect that Aurinia Pharmaceuticals will post 0.81 earnings per share for the current year.

Insider Activity

In other news, CEO Kevin Tang bought 206,005 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were purchased at an average price of $15.28 per share, with a total value of $3,147,756.40. Following the purchase, the chief executive officer owned 13,044,106 shares in the company, valued at approximately $199,313,939.68. The trade was a 1.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders acquired 814,606 shares of company stock valued at $12,455,129. 10.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AUPH. BlackRock Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the second quarter worth $139,037,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Aurinia Pharmaceuticals by 0.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,387,194 shares of the biotechnology company’s stock valued at $54,026,000 after acquiring an additional 13,173 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Aurinia Pharmaceuticals by 4.6% in the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock valued at $24,658,000 after acquiring an additional 73,700 shares in the last quarter. Marshall Wace LLP boosted its holdings in Aurinia Pharmaceuticals by 6.2% in the fourth quarter. Marshall Wace LLP now owns 1,574,957 shares of the biotechnology company’s stock valued at $25,121,000 after purchasing an additional 91,825 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Aurinia Pharmaceuticals by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 1,507,869 shares of the biotechnology company’s stock valued at $24,047,000 after purchasing an additional 22,169 shares during the period. 36.83% of the stock is owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.